Short-Term Outcomes of Heart Transplant Patients Bridged with Impella 5.5 Ventricular Assist Device
ESC Heart Failure · 01.08.2023 · 10 (4) · 2298-2306
DOI: 10.1002/ehf2.14391 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 03.05.2023. Verfasst von Osama Haddad und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Mayo Clinic Hospital, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Heart Transplantation, Heart Failure. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
We sought to investigate the outcomes of heart transplant patients supported with Impella 5.5 temporary mechanical circulatory support. Methods and results Patient demographics, perioperative data, hospital timeline, and haemodynamic parameters were followed during initial admission, Impella support, and post-transplant period. Vasoactive-inotropic score, primary graft failure, and complications were recorded. Between March 2020 and March 2021, 16 advanced heart failure patients underwent Impella 5.5 temporary left ventricular assist device support through axillary approach. Subsequently, all these patients had heart transplantation. All patients were either ambulatory or chair bound during their temporary mechanical circulatory support until heart transplantation. Patients were kept on Impella support median of 19 days (3–31) with the median lactate dehydrogenase level of 220 (149–430). All Impella devices were removed during heart transplantation. During Impella support, patients had improved renal function with median creatinine serum level of 1.55 mg/dL decreased to 1.25 (P = 0.007), pulmonary artery pulsatility index scores increased from 2.56 (0.86–10) to 4.2 (1.3–10) (P = 0.048), and right ventricular function improved (P = 0.003). Patients maintained improved renal function and favourable haemodynamics after their heart transplantation as well. All patients survived without any significant morbidity after their heart transplantation.
Conclusions
Impella 5.5 temporary left ventricular assist device optimizes care of heart transplant recipients providing superior haemodynamic support, mobility, improved renal function, pulmonary haemodynamics, and right ventricular function. Utilizing Impella 5.5 as a direct bridging strategy to heart transplantation resulted in excellent outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, Mayo Clinic Hospital, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.
- Department of Transplantation, Mayo Clinic Hospital, Jacksonville, FL, USA.
ORCID-Profile: Osama Haddad
Zitieren
APA
Haddad, O., Sareyyupoglu, B., Goswami, R. M., Bitargil, M., Patel, P. C., Jacob, S., El-Sayed Ahmed, M. M., Leoni Moreno, J. C., Yip, D. S., Landolfo, K., & Pham, S. M. (2023). Short-Term Outcomes of Heart Transplant Patients Bridged with Impella 5.5 Ventricular Assist Device. ESC Heart Failure, 10(4), 2298-2306. https://doi.org/10.1002/ehf2.14391
Vancouver
Haddad O, Sareyyupoglu B, Goswami RM, Bitargil M, Patel PC, Jacob S, et al. Short-Term Outcomes of Heart Transplant Patients Bridged with Impella 5.5 Ventricular Assist Device. ESC Heart Failure. 2023;10(4):2298-2306. doi:10.1002/ehf2.14391
BibTeX
@article{Haddad2023,
author = {Haddad, Osama and Sareyyupoglu, Basar and Goswami, Rohan M and Bitargil, Macit and Patel, Parag C and Jacob, Samuel and El-Sayed Ahmed, Magdy M and Leoni Moreno, Juan Carlos and Yip, Daniel S and Landolfo, Kevin and Pham, Si M},
title = {Short-Term Outcomes of Heart Transplant Patients Bridged with Impella 5.5 Ventricular Assist Device},
journal = {ESC Heart Failure},
year = {2023},
volume = {10},
number = {4},
pages = {2298--2306},
doi = {10.1002/ehf2.14391}
}
EUVIMED